• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind

cafead

Administrator
Staff member
  • cafead   Sep 12, 2023 at 12:02: PM
via A tiny slice of early-stage data for AstraZeneca’s Daiichi Sankyo-partnered antibody drug conjugate showed a high objective response and disease control rate when combined with immune checkpoint inhibitor Imfinzi in patients with non-small cell lung cancer. (NSCLC).

article source
 

<